Posts of Sam Shahrokhi

Company News
July 21, 2021
CORE ONE LABS’ AKOME BIOTECH PROTECTS NEW AK0003 KETAMINE-BASED BREAKTHROUGH DRUG FORMULATION FOR DEPRESSION TREATMENT
Vancouver, British Columbia, Canada – July 21, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce...
Read more
Company News
July 17, 2021
CORE ONE LABS TO PRESENT ON ITS PROPRIETARY BIOSYNTHETIC PSILOCYBIN TECHNOLOGY AT INVESTOR TOWN HALL EVENT ON AUGUST 4, 2021
Vancouver, British Columbia, Canada – July 17, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”)...
Read more
Company News
July 16, 2021
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
VANCOUVER, British Columbia, July 16, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that it is...
Read more
Company News
July 14, 2021
Core One Labs Announces Effective Date of Share Consolidation
Vancouver, British Columbia, Canada – July 14, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”)...
Read more
Company News
July 08, 2021
Core One Labs Announces New Director
Vancouver, British Columbia, Canada – July 8, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the...
Read more
Company News
June 19, 2021
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
Vancouver, British Columbia, Canada – June 19, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce...
Read more